ORal anticoaGulants in diAbetic and Nondiabetic Patients With nOn-valvular Atrial fibrillatioN (ORGANON)

Phase 4 Completed 300 enrolled University of Pavia

RandomizedParallel-groupOpen-labelTreatment

Summary

Diabetic and nondiabetic patients will be evaluated if they had a first diagnosis of non-valvular atrial fibrillation and in therapy with non-vitamin K oral anticoagulants and with vitamin K oral anticoagulants.

Timeline

Start: 2015-09
Primary completion: 2019-04
Completion: 2019-09

Publications

Derosa G, Rizzo M, Brunetti ND, Raddino R, Gavazzoni M, Pasini G, Gaudio G, Maggi A, D'Angelo A, De Gennaro L, Maffioli P. ORal anticoaGulants in diAbetic and Nondiabetic patients with nOn-valvular atrial fibrillatioN (ORGANON). J Diabetes Complications. 2023 Aug;37(8):108512. doi: 10.1016/j.jdiacomp.2023.108512. Epub 2023 May 20.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Acenocumarole	Unknown	—	Oral
Comparator	Apixaban	Small molecule	—	Oral
Comparator	Dabigatran	Unknown	—	Oral
Comparator	Edoxaban	Small molecule	—	Oral
Comparator	Rivaroxaban	Other / unclassified	—	Oral
Comparator	Warfarin	Small molecule	—	Oral

ORal anticoaGulants in diAbetic and Nondiabetic Patients With nOn-valvular Atrial fibrillatioN (ORGANON)

Summary

Timeline

Publications

Drugs

Indications